<DOC>
	<DOCNO>NCT00003706</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Chemotherapy drug may different effect patient different degree kidney function . PURPOSE : Phase I trial study effectiveness LY231514 treat patient locally advance metastatic solid tumor vary degree kidney function .</brief_summary>
	<brief_title>LY231514 Treating Patients With Locally Advanced Metastatic Solid Tumors Varying Degrees Kidney Function</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxic effect maximum tolerate dose ( MTD ) LY231514 patient metastatic locally advanced solid tumor vary degree renal function . II . Determine recommend dose LY231514 patient population . III . Examine effect renal dysfunction pharmacokinetics LY231514 patient population . IV . Examine relationship impair renal function , drug exposure , drug effect patient . V. Gather data development LY231514 dose nomogram base renal function . VI . Collect preliminary data regard antitumor effect LY231514 patient population . OUTLINE : This open label , dose escalation study . Patients stratify accord renal function . Group 1 consist patient normal renal function , group 2 , 3 , 4 consist patient mild , moderate , severe renal impairment . All patient receive LY231514 IV 10 minute every 3 week . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient treat escalate dos LY231514 within treatment group . If dose limit toxicity ( DLT ) observe 1 3 patient give dose level , 3 additional patient study . The maximum tolerate dose define dose level le 2 6 patient experience DLT . Patients follow death . PROJECTED ACCRUAL : Up 50 patient accrue study .</detailed_description>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic locally advanced solid tumor fail standard therapy standard therapy exist Measurable evaluable disease No active , symptomatic brain metastases No leukemia , lymphoma , multiple myeloma No significant pleural peritoneal effusion PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 3 time ULN ( great 5 time ULN due liver disease ) Albumin least 2.0 g/dL Renal : Not specify Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study No active infection serious concurrent systemic disorder No second primary malignancy past 5 year except carcinoma situ cervix adequately treat basal cell carcinoma skin No body surface area great 3 m2 PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy No concurrent routine use filgrastim ( GCSF ) sargramostim ( GMCSF ) Chemotherapy : At least 4 week since prior chemotherapy ( 6 week since nitrosoureas mitomycin ) recover No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy ( except contraceptive corticosteroid ) Radiotherapy : At least 4 week since prior radiotherapy ( include wide field pelvic radiation ) No concurrent radiotherapy Surgery : Not specify Other : At least 4 week since prior investigational agent Concurrent warfarin heparin allow No aspirin nonsteroidal antiinflammatory 2 day , day , 2 day LY231514 administration ( 5 day longacting agent ) No concurrent nonsteroidal antiinflammatory drug salicylate long halflife e.g. , naproxen , piroxicam , diflunisal , nabumetone ) No concurrent experimental medication No concurrent dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>